Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (91-100 of 539) with videos related to

Pageof 54
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myelomaChristos Sachpekidis, Jens Hillengass, Hartmut Goldschmidt, et al.
Clinical Nuclear Medicine|March 19, 2015
(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rateChristos Sachpekidis, Elias K Mai, Hartmut Goldschmidt, et al.
Blood|August 30, 2002
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myelomaKai Neben, Joannis Mytilineos, Thomas M Moehler, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2005
Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomised, prospective, controlled trialTorben Ostendorf, Andrea Meinhold, Christoph Harter, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 8, 2003
No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvementMartin Zeier, Jolanta Perz, Reinhold P Linke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Annals of Hematology|July 3, 2007
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantationMathias Witzens-Harig, Rüdiger Waldherr, Joerg Beimler, et al.
Leukemia & Lymphoma|October 24, 2019
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsKatja Weisel, Istvan Majer, Lucy DeCosta, et al.
Radiology|September 21, 2010
Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systemsKerstin Fechtner, Jens Hillengass, Stefan Delorme, et al.
Pageof 54

Showing results (91-100 of 539) with videos related to

Sort By:
Pageof 54
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myelomaChristos Sachpekidis, Jens Hillengass, Hartmut Goldschmidt, et al.
Clinical Nuclear Medicine|March 19, 2015
(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rateChristos Sachpekidis, Elias K Mai, Hartmut Goldschmidt, et al.
Blood|August 30, 2002
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myelomaKai Neben, Joannis Mytilineos, Thomas M Moehler, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2005
Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomised, prospective, controlled trialTorben Ostendorf, Andrea Meinhold, Christoph Harter, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 8, 2003
No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvementMartin Zeier, Jolanta Perz, Reinhold P Linke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Annals of Hematology|July 3, 2007
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantationMathias Witzens-Harig, Rüdiger Waldherr, Joerg Beimler, et al.
Leukemia & Lymphoma|October 24, 2019
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsKatja Weisel, Istvan Majer, Lucy DeCosta, et al.
Radiology|September 21, 2010
Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systemsKerstin Fechtner, Jens Hillengass, Stefan Delorme, et al.
Pageof 54